secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000920148-23-000032
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp appoints Brian Caveney as President Early Development & Chief Medical Officer amid spin-off prep
--------------------------------------------------------------------------------

- Brian J. Caveney appointed Executive Vice President, President Early Development & Chief Medical and Scientific Officer effective May 1, 2023.
- His base salary increased to $650,000 as part of the organizational restructuring for the planned spin-off.
- He will receive RSU and performance share awards each valued at $67,000, plus a stock option award valued at $201,000 on May 5, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014823000032/0000920148-23-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014823000032/lh-20230501.htm
  HTML page:      https://secwatch.observer/filing/0000920148-23-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer